


PRESS RELEASE

VIROCLINICS-DDL AND INFINITY BIOLOGIX DEEPEN THEIR PARTNERSHIP



Rotterdam, The Netherlands, New Brunswick NJ, United States, 14 September 2020

The two companies bring their existing partnership to the next level by developing customized services to assist pharma, biotech and governmental clients with clinical diagnostics and global logistical services.

Viroclinics-DDL and Infinity BiologiX (IBX), formerly known as RUCDR Infinite Biologics, started their partnership five years ago to support large scale phase 2/ phase 3 clinical trials in the US and Canada regions. “We initially looked for a highly specialized strategic partner, with expertise in the field of laboratory processing services. IBX has been able to meet and exceed our expectations managing tight clinical trial deadlines” said Davide Molho DVM, CEO Viroclinics-DDL. “Processing laboratories are of vital importance to maintain the chain of custody and integrity of unique clinical samples, collected during clinical trials and shipped to a testing laboratory. This is especially the case for virology and pandemic related studies. IBX is capable of scaling-up capacity and operations to absorb peak in demand without compromising quality or timelines. With our joint experiences in the field of virology we are highly capable of supporting COVID-19 studies”. Dr. Andrew Brooks, CEO and CSO of IBX continued: “Now more than ever, it is of the utmost importance to utilize each other’s strengths and develop logistical and diagnostic services, tailored to the needs of our clients. Viroclinics-DDL has an impressive track record of providing preclinical, clinical diagnostic and logistic services. We strongly believe that we can leverage each other’s unique capabilities with our partnership”. Both parties will join efforts to implement innovative customized service propositions on a global scale and are currently working on many novel solutions, such as a saliva-based test capable simultaneously detecting and distinguishing Influenza A & B virus from SARS-CoV-2 with the same saliva sample. By expanding the strategic partnership, both partners will be able to drive far more impact for their clients and communities.

About Viroclinics-DDL

Viroclinics-DDL is a global leading virology contract research organization, serving the biopharmaceutical community with a broad range of preclinical research, clinical diagnostic, assay development and clinical trial logistic services. Viroclinics-DDL’s extensive experience with clinical and preclinical studies for viruses, including its specialty in respiratory viruses, puts the company at the forefront in supporting the development of vaccines, antibodies and antiviral compounds targeting viral infectious diseases. Our in-house state of the art preclinical and clinical BSL-2 and BSL-3 laboratories allow for complex experiments with highly pathogenic organisms. Viroclinics-DDL is based in The Netherlands and employs more than 270 well-trained, dedicated scientists and technical experts.

For more information: www.viroclinics.com and www.ddl.nl

About Infinity BiologiX

Infinity BiologiX (IBX) is a market-disrupting next-generation central laboratory. It collaborates with, and provides services to researchers and organizations in both the public and private sectors, including sample collection and processing, storage and analytical services, and scientific and technical support in both the research and clinical arenas. The company was previously RUCDR Infinite Biologics before spinning off from Rutgers University-New Brunswick in August 2020 and was the first to receive FDA EAU for Saliva based COVID-19 diagnostics test and at home collection.

For more information please visit www.ibx.bio

Media Contact Viroclinics-DDL

Sander Verkerk, Marketing & Communications Manager
marketing@viroclinics.com
P: +31 88 668 4787

Media Contact Infinity BiologiX

Colleen McMillen
Colleen.McMillen@Infinity-biologix.com